3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Endometrial Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Sunitinib
2
Everolimus
2
sargramostim
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
lanreotide
1
incomplete Freund's adjuvant
1
fludarabine phosphate
1
cabozantinib
1
belzutifan
1
X-Rays
1
Temozolomide
1
Phantoms, Imaging
1
Octreotide
1
Methods
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Colony-Stimulating Factors
1
Blood Specimen Collection
1
Biopsy
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
Everolimus
×
90 days
×
Clear all
NCT06943755
2026-04-17
STELLAR-311
Exelixis
Phase 2/3
Recruiting
440 enrolled
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled